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SUMMARY
Aims: The 24-week, prospective, randomized, double-blind ACTION study investigated the
efficacy, safety, and tolerability of 13.3 versus 4.6 mg/24 h rivastigmine patch in patients
with severe Alzheimer’s disease (AD). Methods: Patients had probable AD and Mini–
Mental State Examination scores ≥3–≤12. Primary outcome measures were as follows:
Severe Impairment Battery (SIB) and AD Cooperative Study–Activities of Daily Living
scale–Severe Impairment Version (ADCS-ADL-SIV). Secondary outcomes were as follows:
ADCS-Clinical Global Impression of Change (ADCS-CGIC), 12-item Neuropsychiatric
Inventory (NPI-12), and safety/tolerability. Results: Of 1014 patients screened, 716 were
randomized to 13.3 mg/24 h (N = 356) or 4.6 mg/24 h (N = 360) patch. Baseline charac-
teristics/demographics were comparable. Completion rates were as follows: 64.3%
(N = 229) with 13.3 mg/24 h and 65.0% (N = 234) with 4.6 mg/24 h patch. The 13.3 mg/
24 h patch was significantly superior to 4.6 mg/24 h patch on cognition (SIB) and function
(ADCS-ADL-SIV) at Week 16 (P < 0.0001 and P = 0.049, respectively) and 24 (primary
endpoint; P < 0.0001 and P = 0.025). Significant between-group differences (Week 24)
were observed on the ADCS-CGIC (P = 0.0023), not NPI-12 (P = 0.1437). A similar propor-
tion of the 13.3 mg/24 h and 4.6 mg/24 h patch groups reported adverse events (AEs;
74.6% and 73.3%, respectively) and serious AEs (14.9% and 13.6%). Conclusions: The
13.3 mg/24 h patch demonstrated superior efficacy to 4.6 mg/24 h patch on SIB and
ADCS-ADL-SIV, without marked increase in AEs, suggesting higher-dose patch has a favor-
able benefit-to-risk profile in severe AD.
Introduction
As patients with Alzheimer’s disease (AD) progress to severe
stages, there is further degeneration of cortically projecting
cholinergic neurons and changes in brain cholinesterase levels
[1] associated with progressive impairments in memory,
cognition, behavior, and performance of activities of daily
living (ADL).
Cholinesterase inhibitors partially compensate for cholinergic
deficits, providing symptomatic relief. Three cholinesterase
inhibitors are widely approved for mild-to-moderate AD; rivastig-
mine (Exelon, Novartis Pharmaceuticals Corporation, East
Hanover, NJ, USA), donepezil (ARICEPT, Eisai Inc., Woodcliff
Lake, NJ, USA), and galantamine (Razadyne, Janssen Pharma-
ceutical N.V., Beerse, Belgium) [2–5]. Until recently, treatment
options for severe AD were limited; donepezil is indicated for mod-
erate-to-severe AD in the USA [4] and memantine (N-methyl-D-
aspartate receptor antagonist) for moderate-to-severe AD in the
USA and several other countries worldwide [6].
Rivastigmine shows dose-dependent efficacy on cognition,
ADL, and global functioning [7,8]. The OPTIMA (OPtimising
Transdermal Exelon In Mild-to-moderate AD) study demonstrated
significantly greater efficacy on ADL with 13.3 mg/24 h (15 cm2)
versus 9.5 mg/24 h (10 cm2) rivastigmine patch in patients with
mild-to-moderate AD who showed functional and cognitive
decline during preceding open-label treatment with 9.5 mg/24 h
patch [9].
Pooled analysis of clinical trial data suggests rivastigmine may
continue to provide benefits at more advanced stages of disease
[10,11]. A randomized, double-blind, study demonstrated that
oral rivastigmine was efficacious compared with placebo in
moderately severe AD [12].
The objective of the ACTION (ACTivities of daily living and
cognitION) study was to compare the efficacy, safety, and tolera-
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bility of 13.3 mg/24 h (15 cm2) versus 4.6 mg/24 h (5 cm2) riv-
astigmine patch in patients with severe AD.
Materials and Methods
Patients
Patients were male/female, aged ≥50 years, with probable AD
(original 1984 National Institute of Neurological and Communica-
tive Disorders and Stroke and AD and Related Disorders Associa-
tion criteria) [13], and Mini–Mental State Examination (MMSE)
[14] scores ≥3–≤12. Magnetic resonance imaging/computed
tomography, used in the diagnosis of probable AD, was required
within the prior 2 years. Patients were living with someone in the
community or were in regular contact with their primary care-
giver. Patients in assisted living facilities were eligible provided
assessment could take place at the study site, and a caregiver was
identified [15].
Exclusion criteria included any advanced/severe/progressive/
unstable disease that could interfere with response to study treat-
ment; patients living in/permanently placed during the study/
likely (physicians’ opinion) to be placed in a nursing home within
the next 7 months; current medical/neurological condition other
than AD that could be the primary cause of dementia; current
diagnosis of probable/possible vascular dementia, uncontrolled
seizure disorder, severe/unstable cardiovascular disease,
bradycardia, sick-sinus syndrome or conduction defects; current
diagnosis of acute/severe/unstable asthmatic conditions; current
diagnosis of uncontrolled peptic ulceration or gastrointestinal
bleeding within the previous 3 months; and/or a history (past
year) or current diagnosis of cerebrovascular disease. Patients
were also excluded if they had a Diagnostic and Statistical Manual
of Mental Disorders diagnosis of major depression [16], unless
successfully treated (antidepressant without anticholinergic
properties) in a stable regimen for ≥4 weeks; clinically significant
urinary obstruction; allergy to vitamin E-containing products,
sensitivity to cholinergic drugs, or skin lesion/disorder that would
prevent patch use; history of malignancy (≤5 years); use of cholin-
esterase inhibitors/other approved AD treatments 2 weeks prior
(except stable memantine if taken for ≥3 months); use of centrally
acting cholinergic drugs/any investigational drug for 4 weeks
prior; use of peripheral anticholinergic drugs/selegiline, or new
psychotropic/dopaminergic drugs if not taken at stable dose, for
4 weeks prior [15].
Standard Protocol Approvals, Registrations, and
Patient Consents
The protocol and amendments were reviewed by Independent
Ethics Committees or Institutional Review Boards. The study was
conducted in accordance with Good Clinical Practice and the ethi-
cal principles of the Declaration of Helsinki. All patients, or if they
lacked capacity, their legally authorized representative, provided
written informed consent prior to participating. This study is
registered (clinicaltrials.gov NCT00948766).
Protocol amendments after study-start included clarifying
enrollment eligibility requirements and revising instructions for
patch application to prevent administration errors.
Study Design
ACTION was a 24-week, prospective, randomized, double-blind,
double-dummy, multicenter trial conducted at 82 centers across
the USA between July 22, 2009 and January 10, 2012 (last-
patient-last-visit). Patients were randomized (1:1) at Week 0 to
13.3 mg/24 h or 4.6 mg/24 h rivastigmine patch. All patients
initiated treatment on 4.6 mg/24 h patch. Patients randomized
to 13.3 mg/24 h patch were up-titrated (start of Week 4) to
9.5 mg/24 h patch and at the start of Week 8 to 13.3 mg/24 h
patch. Patients randomized to 4.6 mg/24 h patch remained at that
dose for the 8-week titration. Patients were maintained at the tar-
get dose for the 16-week maintenance period [15]. The 4.6 mg/
24 h patch group also received 10 cm2 (from start of Week 4) and
15 cm2 placebo patches (from start of Week 8–24). The 13.3 mg/
24 h patch group received 5 cm2 placebo patches throughout.
For patients missing >3 consecutive days of treatment due to
tolerability problems, treatment could be restarted (4.6 mg/24 h)
and the dose increased after 2 weeks minimum. If tolerability was
improved and the patient had missed treatment for ≤3 consecutive
days, treatment could be restarted at the same dose level, and
titration resumed. Further doses could be skipped if subsequent
titration led to tolerability problems. In the maintenance phase,
patients were required to be able to tolerate the maximum dose
and were not permitted to down-titrate, so as not to compromise
blinding.
Primary Outcomes
Primary outcomes were the change from baseline–Week 24 on
the Severe Impairment Battery (SIB) [17] and AD Cooperative
Study–ADL scale–Severe Impairment Version (ADCS-ADL-SIV)
[18].
Secondary Outcomes
Secondary outcomes were as follows: ADCS–Clinical Global
Impression of Change (ADCS-CGIC) [19] score at Week 24, and
the change from baseline–Week 24 on the 12-item Neuropsychi-
atric Inventory (NPI-12) [20].
In addition to Week 24 (primary endpoint), all efficacy
measures were assessed at Weeks 8 and 16.
Evaluations to maintain safety included the following: incidence
of adverse events (AEs) and serious AEs (SAEs); laboratory tests;
electrocardiogram analysis; assessments of skin irritation and vital
signs; and the discontinuation rate due to AEs.
Sample Size, Randomization, and Blinding
It was estimated that 338 patients were required/group to achieve
an effect size of 0.25 on the primary efficacy variables and overall
power between 82% and 85%, assuming a correlation coefficient
between the co-primary efficacy variables of 0.3–0.6. To adjust for
the 5% of patients estimated to be lost to follow-up, a total sample
size of 712 was planned.
Centralized block randomization was performed by an interac-
tive voice response system. The investigator/his/her delegate was
required to contact the interactive voice response system and
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confirm patient eligibility. The interactive voice response system
assigned a randomization number, linking the patient to a treat-
ment arm, and specified a unique medication number to dispense
the first package of study medication. The randomization scheme
was reviewed and approved by the Novartis Biostatistics Quality
Assurance Group.
Patients, study investigators, and data analysts remained
blinded from randomization until database lock. Unblinding
occurred only in case of patient emergencies and at study
end.
Statistical Analyses
The null hypotheses were 13.3 mg/24 h would not differ from
4.6 mg/24 h patch in the change from baseline–Week 24 on
ADCS-ADL-SIV/SIB total score. The alternative was 13.3 mg/24 h
differs from 4.6 mg/24 h patch in change from baseline–Week 24
in ADCS-ADL-SIV and SIB total score. Significant efficacy on both
primary outcomes was required to demonstrate superiority of
13.3 mg/24 h over 4.6 mg/24 h patch.
Analyses of primary outcomes were based on the modified full
analysis set (all randomized patients who received ≥1 dose of
study medication and had ≥1 postbaseline measurement). Imputa-
tion of missing values was performed following the last-observa-
tion-carried-forward approach. Treatment differences in the
change from baseline on the ADCS-ADL-SIV, SIB, and NPI-12
were compared using least-squares means derived using analysis
of covariance (ANCOVA) with treatment and pooled center as fac-
tors and corresponding baseline score as a covariate. ADCS-CGIC
scores were analyzed using the Cochran–Mantel–Haenszel test,
with modification relative to an identified distribution integral
transformation scores adjusting for pooled center.
Longitudinal analysis of the change from baseline for the co-
primary efficacy variables was performed for the modified full
analysis set using observed cases. An unstructured covariance
matrix for the repeated measures within each patient was applied.
Explanatory variables included treatment, pooled center, week,
treatment-by-week, and corresponding baseline. Treatment
groups were compared based on least-squares means. The SAS
procedure PROCMIXED was used.
Sensitivity analyses were conducted using a pattern mixture
model considering missing data (completers and noncompleters)
for each co-primary efficacy variable and were based on a
repeated-measures ANCOVA model with treatment, pooled
center, week, dropout, treatment-by-week, treatment-by-dropout
as factors, and baseline as a covariate, assuming an unstructured
within-subject covariance matrix.
Safety analyses were based on the safety set (all patients who
received ≥1 dose of study medication and had ≥1 safety assessment
postbaseline) and were summarized according to treatment
received.
For continuous variables, number of patients with observed
values (n), mean, standard deviation (SD), 95% confidence inter-
vals (95% CI), minimum, and maximum were calculated.
Figure 1 Patient disposition throughout the
study (randomized population). AEs, adverse
events; N, number of patients in the
population; n, number of patients with an
assessment. One patient in each treatment
group was randomized, but was not exposed
to study medication.
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Categorical variables were summarized by frequency counts and
percentages. Unless otherwise specified, all statistical tests were
conducted against a two-sided alternative hypothesis; P-values
below 0.05 were considered significant.
Results
Study Participants
Of 1014 patients screened, 716 were enrolled and randomized to
13.3 mg/24 h (N = 356) or 4.6 mg/24 h rivastigmine patch
(N = 360). Similar proportions of each group completed the study
(Figure 1). Baseline demographics and characteristics were
comparable (Table 1).
Dosing
All patients randomized to 4.6 mg/24 h patch received this dose
at Week 24. Of those patients randomized to 13.3 mg/24 h patch,
85.1% received the target dose at Week 24; 6.5% and 8.5%
received 9.5 mg/24 h or 4.6 mg/24 h patch, respectively. Mean
(SD) duration of exposure was 19.6 (7.9) weeks in the 13.3 mg/
24 h patch group and 20.1 (7.6) weeks in the 4.6 mg/24 h patch
group.
Concomitant Medications
Overall, 96.1% and 95.8% of the 13.3 mg/24 h and 4.6 mg/24 h
patch groups, respectively, were taking concomitant medication
and/or using nondrug therapies. There were no notable
differences in concomitant medication use between groups; the
most commonly used were platelet aggregation inhibitors (43.9%,
13.3 mg/24 h; 40.4%, 4.6 mg/24 h patch group) and 3-hydroxy-
3-methyl-glutaryl-CoA reductase inhibitors (40.3% and 41.2%,
respectively).
Psychotropic medications were taken by 83.9% and 82.5% of
the 13.3 mg/24 h and 4.6 mg/24 h patch groups, respectively, and
were most commonly antidementia drugs (primarily memantine
hydrochloride; 60.6%), and selective serotonin reuptake inhibitors
(38.7%).
Primary Outcome Analyses
SIB scores decreased from baseline in both groups throughout the
study. Significantly less deterioration was observed at Weeks 16
(P < 0.0001; difference 4.9 points; 95% CI 2.8, 6.9) and 24
(primary endpoint; P < 0.0001; difference 4.9 points; 95% CI 2.8,
7.0) with 13.3 mg/24 h compared with 4.6 mg/24 h patch
(Figure 2A; Table 2). Similar findings were observed in longitudi-
nal (P < 0.0001; difference 5.3 points; 95% CI 3.1, 7.5 at Week 16
and P < 0.0001; difference 5.3 points; 95% CI 3.0, 7.7 at Week
24) and sensitivity analyses (P < 0.0001; difference 6.0 points;
95% CI 3.6, 8.3 at Week 16 and P < 0.0001; difference 6.1 points,
95% CI 3.6, 8.6 at Week 24).
In both groups, the ADCS-ADL-SIV score decreased from base-
line throughout the study. Significantly less deterioration was
observed on the ADCS-ADL-SIV with 13.3 mg/24 h versus
4.6 mg/24 h patch at Weeks 16 (P = 0.049; difference 1.0 point;
95% CI 0.0, 2.0) and 24 (primary endpoint; P = 0.025; difference
1.2 points; 95% CI 0.2, 2.3; Figure 2B; Table 2). These findings
were supported by the longitudinal (P = 0.057; difference 1.0
point; 95% CI 0.0, 2.1 at Week 16 and P = 0.031; difference 1.3
points; 95% CI 0.1, 2.6 at Week 24) and sensitivity analyses
(P = 0.032; difference 1.3 points; 95% CI 0.1, 2.5 at Week 16 and
P = 0.016; difference 1.6 points; 95% CI 0.3, 3.0 at Week 24).
Secondary Outcome Analyses
The between-group difference in the distribution of ADCS-CGIC
ratings was significant (P = 0.0023; Table 2). A significantly
higher percentage of patients receiving 13.3 mg/24 h compared
with 4.6 mg/24 h patch displayed improvement in clinical status
from baseline–Week 24 (P = 0.0094). There were no significant
between-group differences at Week 24 on the NPI-12 (Table 2;
P = 0.1437; difference 1.6 points; 95% CI 3.8, 0.6).
Safety and Tolerability
Overall, the incidence of AEs was similar between the 13.3 mg/
24 h and 4.6 mg/24 h patch groups (74.6% [n = 265/355] vs.
73.3% [n = 263/359], respectively; Table 3). By preferred term,
most AEs were more frequent with 13.3 mg/24 h than 4.6 mg/
24 h patch (Table 3), with the exception of agitation, urinary tract
Table 1 Patient demographics and background characteristics by
treatment group (randomized set)
13.3 mg/24 h
rivastigmine
patch
4.6 mg/24 h
rivastigmine
patch Total
N = 356 N = 360 N = 716
Age, years
Mean (SD) 77.6 (8.7) 76.5 (9.4) 77.0 (9.0)
Range 52–96 51–96 51–96
Gender, %
Female 63.8 65.0 64.4
Predominant race, %
Caucasian 86.0 88.6 87.3
Black 7.9 5.3 6.6
Other 6.2 6.1 6.2
MMSE score
Mean (SD) 8.8 (2.9) 8.8 (3.0) 8.8 (2.9)
Range 3.0–13.0 3.0–19.0 3.0–19.0
Years since diagnosis of AD
Mean (SD) 4.3 (2.7) 4.0 (2.7) 4.1 (2.7)
Range 0.0–19.1 0.0–18.3 0.0–19.1
Years since diagnosis
of severe dementia
Mean (SD) 1.2 (1.9) 1.2 (1.6) 1.2 (1.7)
Range 0.0–12.2 0.0–9.8 0.0–12.2
Patients living situation, %
Home 90.4 88.1 89.2
Assisted living facility 7.6 9.7 8.7
Other 2.0 2.2 2.1
AD, Alzheimer’s disease; MMSE, Mini–Mental State Examination; N, num-
ber of patients in the randomized population; SD, standard deviation.
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infection, application site dermatitis, anxiety, confusional state,
constipation, hallucination, and peripheral edema.
Gastrointestinal AEs (nausea, vomiting, and diarrhea) were
more frequent with 13.3 mg/24 h than 4.6 mg/24 h patch
(nausea: 6.2% vs. 2.8%; vomiting 7.0% vs. 2.5%; diarrhea: 6.5%
vs. 5.3%, respectively). Approximately a quarter of all patients
experienced a skin irritation AE (26.5%, 13.3 mg/24 h patch;
24.0%, 4.6 mg/24 h patch).
The incidence of deaths during the study period and SAEs was
comparable between the 13.3 mg/24 h and 4.6 mg/24 h patch
groups (deaths: 0.3% in both groups; SAEs: 14.9% vs. 13.6%,
respectively; Table 4). The deaths were not considered study-
drug-related. SAEs were most commonly psychiatric disorders
(3.1% and 4.2%, 13.3 mg/24 h and 4.6 mg/24 h patch group,
respectively). Overall, 8.2% of the 13.3 mg/24 h and 4.5% of the
4.6 mg/24 h patch group discontinued due to SAEs. Discontinua-
tions due to nonserious AEs (most commonly psychiatric
disorders) were numerically higher with 13.3 mg/24 h (13.5%)
than 4.6 mg/24 h patch (10.9%). Interestingly, discontinuations
due to skin irritations at the application site were lower with
13.3 mg/24 h (1.7%) than 4.6 mg/24 h patch (2.5%; Table 4).
Three clinically notable vital sign abnormalities were reported
as AEs. Two patients experienced weight gain, classed as nonseri-
ous, mild in severity, and not suspected to be study-drug-related.
One patient had an increase in systolic blood pressure, which was
nonserious, mild, and suspected to be study-drug-related.
Conclusions
This was the first study to assess the efficacy, safety, and tolerabil-
ity of 13.3 mg/24 h rivastigmine patch in patients with severe
AD. As expected given the progressive nature of disease in this
population, both treatment groups showed deterioration (SIB and
ADCS-ADL-SIV) over the course of this 24-week study. However,
13.3 mg/24 h patch was associated with superior efficacy on the
SIB and ADCS-ADL-SIV, compared with 4.6 mg/24 h patch at
Weeks 16 and 24 (co-primary endpoint) in the primary last-obser-
vation-carried-forward analyses. Supporting the primary findings,
13.3 mg/24 h patch demonstrated efficacy on global function
(ADCS-CGIC), providing evidence for clinical relevance of the
high-dose treatment effects. Longitudinal and sensitivity analyses
were also supportive of the primary findings. No significant differ-
ences were observed on behavior (NPI-12) or based on the simi-
larity in incidence of psychiatric disorders as AEs between groups.
There tended to be a slight dose-related increase in incidence of
specific AEs, including gastrointestinal-related (i.e., nausea,
vomiting, decreased appetite, and weight loss), and application
site erythema with 13.3 mg/24 h versus 4.6 mg/24 h patch. Yet,
overall incidences of AEs were similar between groups suggesting
that, generally, patients were able to tolerate higher doses without
negatively impacting tolerability. Preliminary safety review of the
13.3 mg/24 h rivastigmine patch suggests a profile consistent with
previous studies [9].
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Figure 2 Least-squares means change from
baseline to Week 24 on (A) SIB and (B)
ADCS-ADL-SIV (modified full analysis set).
ADCS-ADL-SIV, Alzheimer’s Disease
Cooperative Study–Activities of Daily Living
scale–Severe Impairment Version; SEM,
standard error of the least-squares means; SIB,
Severe Impairment Battery. Error bars
represent the SEM. *P < 0.05; **P < 0.0001
versus 4.6 mg/24 h patch.
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The efficacy findings are supported by previous clinical trials,
pooled, and retrospective analyses, which have suggested
rivastigmine may benefit patients with moderately severe or
severe AD [10–12,21–23]. A 26-week, randomized, controlled
proof-of-concept trial of 3–12 mg/day oral rivastigmine in moder-
ately severe to severe AD demonstrated significant improvements
versus placebo on the SIB (co-primary outcome measure) and
ADCS-CGIC [12], but did not reach significance on the NPI-10
(co-primary outcome measure), NPI-4 or ADCS-ADL [12]. In a
study of 24 mg oral galantamine in severe AD, cognitive function
(SIB) was significantly improved, but no significant treatment
effects were observed on the Minimum Data Set-ADL scale
(co-primary efficacy measures) [24]. Similarly, a study of 10 mg
oral donepezil in severe AD demonstrated greater efficacy versus
placebo on the SIB and Clinician’s Interview-Based Impression of
Change-Plus caregiver input (CIBIC-Plus; co-primary outcome
measures), but not on ADCS-ADL-SIV or NPI [25]. A randomized,
double-blind, 24-week study of 23 mg/day versus 10 mg/day oral
donepezil in moderate-to-severe AD demonstrated significantly
greater efficacy of the higher dose at Week 24 on the SIB [26]. No
significant between-group differences were observed on the co-
primary outcome measure, the CIBIC-Plus, or secondary efficacy
measures (ADCS-ADL or MMSE) [26].
This is the first study to demonstrate efficacy of higher-dose
13.3 mg/24 h rivastigmine patch on maintaining the ability to
perform ADL, assessed as a co-primary outcome. In addition to
cognition, benefits on ADL in severe disease stages are important,
not only for patients, but also for caregivers because patients with
severe AD are more dependent and require greater care than
patients in earlier disease stages [27,28]. Dependency on others to
perform ADL impacts patient quality of life [29]; minimizing
functional decline could enhance quality of life and may decrease
caregiver burden.
As the first study of rivastigmine patch in patients with severe
AD, 4.6 mg/24 h patch was selected as a low-dose active compar-
ator to fully evaluate high-dose patch in this patient population.
Table 2 Primary (SIB and ADCS-ADL-SIV) and secondary (ADCS-CGIC and NPI-12) efficacy outcomes (modified full analysis set)
13.3 mg/24 h
rivastigmine
patch
4.6 mg/24 h
rivastigmine
patch
P-valueN = 338 N = 335
SIB
N (baseline) 336 334
Mean (SD) score at baseline 69.3 (21.5) 68.3 (22.8)
N (Week 24) 313 316
Mean (SD) change from baseline at Week 24 1.6 (13.5) 6.4 (14.0)
Least-squares means (SE) change from baseline at Week 24 1.7 (0.8) 6.6 (0.8)
Least-squares means difference (95% CI) 4.9 (2.8, 7.0) <0.0001
ADCS-ADL-SIV
N (baseline) 333 319
Mean (SD) score at baseline 29.7 (11.3) 29.1 (11.9)
N (Week 24) 310 303
Mean (SD) change from baseline at Week 24 2.6 (6.8) 3.6 (7.7)
Least-squares means (SE) change from baseline at Week 24 2.4 (0.4) 3.6 (0.4)
Least-squares means difference (95% CI) 1.2 (0.2, 2.3) 0.0247
ADCS-CGIC
Week 24, n (%) 0.0023
Marked improvement 3 (1.0) 4 (1.3)
Moderate improvement 11 (3.5) 11 (3.5)
Minimal improvement 63 (20.1) 36 (11.4)
No change 107 (34.2) 92 (29.2)
Minimal worsening 76 (24.3) 99 (31.4)
Moderate worsening 44 (14.1) 60 (19.0)
Marked worsening 9 (2.9) 13 (4.1)
NPI-12
N (baseline) 335 331
Mean (SD) score at baseline 17.3 (15.4) 16.8 (16.7)
N (Week 24) 313 313
Mean (SD) change from baseline at Week 24 0.4 (14.0) 1.2 (16.8)
Least-squares means (SE) change from baseline at Week 24 0.1 (0.8) 1.5 (0.8)
Least-squares means difference (95% CI) 1.6 (3.8, 0.6) 0.1437
ADCS-ADL-SIV, Alzheimer’s Disease Cooperative Study–Activities of Daily Living scale–Severe Impairment Version; ADCS-CGIC, Alzheimer’s Disease
Cooperative Study–Clinical Global Impression of Change; CI, confidence interval; N, number of patients with an assessment at the given time point;
n, number of patients in a given category; NPI-12, 12-item Neuropsychiatric Inventory; SD, standard deviation; SE, standard error; SIB, Severe Impair-
ment Battery.
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Efficacy of 4.6 mg/24 h patch versus placebo has not been evalu-
ated in a clinical trial setting; however, it was used as a titration
dose in patients with mild-to-moderate AD during both the
OPTIMA and Investigation of transDermal Exelon in ALzheimer’s
disease (IDEAL) studies [9,30]. The 4.6 mg/24 h patch provides
comparable exposure to 3 mg twice daily [31], an oral titration
dose associated with proven efficacy [32]. Based on this compari-
son, it is conceivable that 4.6 mg/24 h patch could have masked
the full extent of the 13.3 mg/24 h patch treatment effect in this
trial. The 9.5 mg/24 h patch is currently the minimum effective
dose and 13.3 mg/24 h patch the maximum effective dose for
patients with mild-to-moderate AD, according to the US prescrib-
ing information [3]. Efficacy of 9.5 mg/24 h patch and the
benefit:risk ratio of 9.5 mg/24 h versus 13.3 mg/24 h patch in
patients with severe AD remains to be investigated in a clinical
trial setting.
In summary, higher-dose 13.3 mg/24 h rivastigmine patch con-
ferred benefits on cognition, ADL, and global functioning in
patients with severe AD, without marked reduction in tolerability.
These findings support previous data and suggest rivastigmine
patch can benefit patients across the disease spectrum [9,30].
Based on the therapeutic benefit observed in this study popula-
tion, the higher-dose rivastigmine patch is now approved in the
USA for the symptomatic treatment of severe AD.
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Table 3 Most frequent AEsa by treatment and preferred term in the
24-week treatment phase
13.3 mg/24 h
rivastigmine
patch
N = 355
n (%)
4.6 mg/24 h
rivastigmine
patch
N = 359
n (%)
Any AE 265 (74.6) 263 (73.3)
Application site
erythema
47 (13.2) 42 (11.7)
Agitation 41 (11.5) 51 (14.2)
Urinary tract
infection
29 (8.2) 34 (9.5)
Application site
dermatitis
27 (7.6) 33 (9.2)
Fall 27 (7.6) 21 (5.8)
Insomnia 25 (7.0) 15 (4.2)
Vomiting 25 (7.0) 9 (2.5)
Diarrhea 23 (6.5) 19 (5.3)
Weight decreased 23 (6.5) 11 (3.1)
Nausea 22 (6.2) 10 (2.8)
Depression 17 (4.8) 15 (4.2)
Decreased appetite 17 (4.8) 5 (1.4)
Anxiety 16 (4.5) 16 (4.5)
Hypertension 13 (3.7) 9 (2.5)
Application site
pruritus
13 (3.7) 8 (2.2)
Confusional state 12 (3.4) 13 (3.6)
Somnolence 12 (3.4) 9 (2.5)
Constipation 11 (3.1) 12 (3.3)
Urinary incontinence 11 (3.1) 10 (2.8)
Application site
irritation
11 (3.1) 9 (2.5)
Dehydration 11 (3.1) 8 (2.2)
Dizziness 11 (3.1) 5 (1.4)
AE, adverse event; N, number of patients in the population; n, number
of patients reporting AE. aOnly AEs with a ≥3% incidence in the
13.3 mg/24 h patch group are shown. A patient with multiple occur-
rences of an AE was counted only once in the AE category. AEs are pre-
sented by descending frequency in the 13.3 mg/24 h patch group.
Table 4 The incidence of deaths, SAEs, and discontinuations due to
AEs and SAEs (safety set).
13.3 mg/24 h
rivastigmine
patch
N = 355
n (%)
4.6 mg/24 h
rivastigmine
patch
N = 359
n (%)
Deathsa 1 (0.3) 1 (0.3)
SAE(s) 53 (14.9) 49 (13.6)
Discontinuations
due to SAE(s)
29 (8.2) 16 (4.5)
Discontinuations
due to non-serious AE(s)
48 (13.5) 39 (10.9)
Discontinuations
due to nausea or vomiting
9 (2.5) 4 (1.1)
Discontinuations due to
skin irritations at the application site
6 (1.7) 9 (2.5)
AE, adverse event; N, number of patients in the population; n, number
of patients reporting AE; SAE, serious adverse event. aDeaths that
occurred during the study period.
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